Tolvaptan may slow eGFR decline in patients with autosomal dominant PKD

Routine use of tolvaptan in clinical practice may slow eGFR decline for patients with autosomal dominant polycystic kidney disease compared with historical controls, data show.“Efficacy of tolvaptan has been demonstrated in controlled clinical trials with highly motivated patients and regular follow-up at PKD centers of excellence,” Ronald D. Perrone, MD, FASN, professor of medicine at the Tufts University School of Medicine in the division of nephrology, told Healio. “The finding of similar efficacy in clinical practice, involving multiple clinicians distributed over variedRead More